KEY TAKEAWAYS
- Ophthalmia neonatorum is conjunctivitis in the first ~4 weeks of life — and timing of onset points to the cause.
- Gonococcal conjunctivitis is the sight-threatening emergency — hyperacute, days 2–5, copious purulent discharge with marked lid edema — it can perforate the cornea and cause blindness within 24 hours.
- Chlamydial conjunctivitis is the commonest infectious cause (days 5–14), usually milder, and risks chlamydial pneumonia — it needs systemic (oral) therapy, not just topical.
- Neonatal ocular prophylaxis (typically erythromycin 0.5% ointment) prevents gonococcal disease but does not reliably prevent chlamydial disease — so maternal prenatal screening/treatment is the more complete strategy.
- Gonococcal treatment is systemic (a single dose of ceftriaxone, with saline irrigation); chlamydial treatment is systemic oral erythromycin/azithromycin.
- Consider HSV (serosanguineous discharge, vesicles, systemic illness) — treat with systemic acyclovir (see the HSV chapter).
1. Clinical Overview
Clinical Overview
Neonatal conjunctivitis is common and mostly mild, but it contains a true ophthalmic emergency — gonococcal ophthalmia — that can destroy vision within a day, and a common infectious cause — chlamydial conjunctivitis — whose importance lies partly outside the eye (pneumonia). Because the organisms are acquired from infected maternal genital secretions during delivery, the disease is closely tied to maternal sexually transmitted infections, and prevention operates on two levels: maternal screening/treatment (the more effective lever) and neonatal ocular prophylaxis (which covers gonococcus but not reliably chlamydia). The clinician's job is to recognize the emergency, treat systemically when indicated, and not mistake a serious infection for a trivial one — while remembering HSV as a systemic threat presenting at the eye.
2. Definitions
| Term | Meaning |
|---|
| Ophthalmia neonatorum | Conjunctivitis in the first ~28–30 days of life. |
| Gonococcal ophthalmia (GON) | Conjunctivitis from Neisseria gonorrhoeae — hyperacute, sight-threatening. |
| Chlamydial conjunctivitis | Conjunctivitis from Chlamydia trachomatis — commonest infectious cause; pneumonia risk. |
| Ocular prophylaxis | Topical agent (e.g., erythromycin 0.5% ointment) given after birth to prevent GON. |
| Chemical conjunctivitis | Mild self-limited irritation (historically from silver nitrate) in the first 24 h. |
3. Causes by Timing (a classic framework)
| Onset | Cause | Features |
|---|
| First 24 h | Chemical (silver nitrate — now rare) | Mild, self-limited |
| Days 2–5 | Gonococcal | Hyperacute, copious purulent discharge, marked lid edema/chemosis — emergency |
| Days 5–14 | Chlamydial | Mucopurulent, milder; pneumonia risk; commonest infectious cause |
| ~1–2 weeks (6–14 d) | HSV | Serosanguineous/non-purulent; ± vesicles/systemic HSV |
| Variable | Other bacteria (Staph, Strep, gram-negatives) | Variable |
Causes by Timing (a classic framework)
(Timing overlaps — use it as a guide, not a rule.)
4. Pathophysiology & Transmission
Pathophysiology & Transmission
- Acquired during delivery from infected maternal genital secretions (gonorrhea, chlamydia); an infant born to an infected mother has a substantial chance of developing conjunctivitis.
- Gonococcus can penetrate intact corneal epithelium → rapid corneal ulceration/perforation → blindness.
- Chlamydia also colonizes the nasopharynx → risk of afebrile pneumonia (weeks 2–12), which is why treatment must be systemic.
5. Clinical Presentation
Clinical Presentation
- Conjunctival injection, discharge, and eyelid swelling — severity and character vary by cause.
- Gonococcal: hyperacute, profuse purulent discharge, marked lid edema/chemosis — a red-flag emergency.
- Chlamydial: mucopurulent, milder, often days 5–14; watch for respiratory symptoms (pneumonia).
- HSV: serosanguineous/non-purulent discharge, ± vesicles, ± systemic illness.
6. Diagnostic Approach
Diagnostic Approach
- Gram stain (gram-negative intracellular diplococci → gonococcal), culture, and NAAT (for gonorrhea and chlamydia).
- Chlamydia: conjunctival scraping (needs epithelial cells) / NAAT; Giemsa may show inclusions.
- HSV: viral PCR/culture; evaluate for systemic HSV (see the HSV chapter).
- Assess for systemic involvement — disseminated gonococcal infection (sepsis, arthritis, meningitis); chlamydial pneumonia; systemic HSV.
- In severe/suspicious cases, treat empirically while awaiting results (topical + systemic — see below).
7. Management
Management
Gonococcal conjunctivitis — EMERGENCY (systemic therapy)
- Single dose of ceftriaxone (commonly 25–50 mg/kg IV/IM, max ~125 mg) plus frequent saline eye irrigation.
- ⚠️ In significant hyperbilirubinemia, use an alternative (e.g., cefotaxime) — ceftriaxone can displace bilirubin.
- Hospitalize; evaluate for disseminated infection; treat the mother and partners.
Chlamydial conjunctivitis — systemic therapy
- Oral erythromycin (or azithromycin) for ~14 days — topical alone is insufficient (systemic therapy clears the nasopharynx and reduces pneumonia risk). A ~20% failure rate may require a repeat course.
- ⚠️ Oral erythromycin in young infants is associated with infantile hypertrophic pyloric stenosis — counsel families.
- Treat the mother and partners.
HSV conjunctivitis
- Systemic acyclovir + a topical ophthalmic antiviral (e.g., ganciclovir/trifluridine), with ophthalmology involvement (see the HSV chapter).
Chemical conjunctivitis
- Supportive (lubrication); self-limited.
Empiric (severe/unclear, pending results)
- Topical erythromycin + a systemic third-generation cephalosporin while awaiting Gram stain/culture in severe cases.
8. Prevention
Prevention
- Neonatal ocular prophylaxis: erythromycin 0.5% ophthalmic ointment (the FDA-approved agent in the US) shortly after birth — prevents gonococcal disease (USPSTF grade A). It does NOT reliably prevent chlamydial conjunctivitis.
- Maternal prenatal screening and treatment for gonorrhea and chlamydia is the more complete prevention strategy (addresses the source; also prevents chlamydial disease and pneumonia).
- Antimicrobial resistance (e.g., in gonococcus) is evolving — verify current prophylaxis/treatment recommendations.
Giving prophylaxis correctly, and when parents refuse (Baylor Ed. 33)
- Why it still matters: gonococcal disease occurs in about 0.3 per 1000 live births. Before Credé introduced ocular prophylaxis in 1881, gonococcal conjunctivitis was the leading cause of infant blindness, and it remains important in developing countries. Ocular prophylaxis is mandated in all 50 US states.
- Technique: a 1–2 cm ribbon of 0.5% erythromycin ointment in each eye within 2 hours of birth. Do not flush it out; excess can be wiped away after 1 minute.
- Refusal: the provider discusses the purpose of prophylaxis and the consequences of declining. If the parent still refuses, document the discussion in detail in the permanent medical record — Texas law requires the attendant at birth to provide prophylaxis. Obligations elsewhere vary by jurisdiction.
- Look at the eyes, not just treat them: mucopurulent material expressed from the puncta by pressing on the lacrimal sac suggests nasolacrimal obstruction — repeated sac massage at the medial canthus flushes stagnant tears and reduces infection. A firm bluish mass beside the medial canthus is a congenital dacryocystocele, which can become infected — refer promptly to ophthalmology. Conjunctival redness or exudate is abnormal.
9. Monitoring
Monitoring
- Clinical response (discharge, lid edema, cornea) — gonococcal disease needs close observation for corneal involvement.
- Systemic evaluation (disseminated gonococcal infection; chlamydial pneumonia).
- Note: routine "test of cure" is not generally recommended with NAAT (detects non-viable organisms for weeks).
- Ensure maternal/partner treatment.
10. Complications
Complications
- Gonococcal: corneal ulceration/perforation, blindness; disseminated gonococcal infection (sepsis, arthritis, meningitis).
- Chlamydial: pneumonia; conjunctival/corneal scarring (less common).
- HSV: keratitis, systemic HSV disease.
11. Safety Warnings
Safety Warnings
- ⚠️ Gonococcal ophthalmia can blind within 24 hours — treat urgently and systemically (ceftriaxone + irrigation).
- ⚠️ Chlamydial conjunctivitis needs SYSTEMIC therapy — topical alone won't clear the nasopharynx or prevent pneumonia.
- ⚠️ Ocular prophylaxis prevents gonococcal, not chlamydial, disease — maternal screening/treatment matters.
- ⚠️ Watch ceftriaxone in hyperbilirubinemia (use cefotaxime); counsel on pyloric stenosis with oral erythromycin.
- ⚠️ Consider HSV (vesicles/serosanguineous discharge/systemic illness) — treat systemically.
- ⚠️ Treat the mother and partners.
12. Common Mistakes
Common Mistakes
- Underestimating gonococcal ophthalmia (delaying systemic therapy).
- Treating chlamydial conjunctivitis with topical therapy only.
- Assuming prophylaxis prevents chlamydia (it doesn't reliably).
- Using ceftriaxone in a hyperbilirubinemic infant without considering alternatives.
- Missing HSV (systemic threat).
- Forgetting to treat the mother/partners.
- Ordering an unnecessary NAAT test of cure.
13. Clinical Pearls
Clinical Pearls
- 💡 Timing hints the cause: day 1 chemical, days 2–5 gonococcal, days 5–14 chlamydial, ~1–2 wk HSV.
- 💡 Hyperacute purulent discharge + lid edema = gonococcus — a sight emergency.
- 💡 Chlamydia needs the pill, not just the drop — systemic therapy.
- 💡 Prophylaxis covers GC, not chlamydia — screen the mother.
- 💡 Green-tinged serosanguineous discharge or vesicles → think HSV.
- 💡 Treat the couple, not just the eye.
14. Summary Table
Summary Table
| Cause | Onset | Severity | Treatment |
|---|
| Chemical | <24 h | Mild | Supportive/lubrication |
| Gonococcal | Days 2–5 | Hyperacute — emergency | Ceftriaxone (single dose) + saline irrigation; systemic workup |
| Chlamydial | Days 5–14 | Milder; pneumonia risk | Oral erythromycin/azithromycin × 14 d (systemic) |
| HSV | ~1–2 wk | Systemic threat | Systemic acyclovir + topical antiviral (see HSV chapter) |
| Prevention | — | — | Erythromycin 0.5% ointment (GC, not chlamydia) + maternal screening/treatment |
15. Step-by-Step Bedside Algorithm
NEWBORN with CONJUNCTIVITIS (first ~4 weeks)
│
▼
Assess ONSET + severity + discharge character; Gram stain / culture / NAAT (GC + chlamydia); consider HSV PCR
│
▼
HYPERACUTE, copious PURULENT discharge + marked lid edema (days 2–5)? → GONOCOCCAL — EMERGENCY
→ single-dose CEFTRIAXONE (cefotaxime if hyperbilirubinemic) + frequent SALINE IRRIGATION
→ hospitalize; evaluate DISSEMINATED infection; treat mother/partners
│
▼
Mucopurulent, milder (days 5–14)? → CHLAMYDIAL
→ ORAL ERYTHROMYCIN/AZITHROMYCIN × ~14 d (SYSTEMIC; counsel pyloric stenosis)
→ watch for PNEUMONIA; treat mother/partners
│
▼
Serosanguineous / vesicles / systemic illness? → HSV → SYSTEMIC ACYCLOVIR + topical antiviral (see HSV chapter)
│
▼
First 24 h, mild, self-limited → CHEMICAL → supportive
│
▼
PREVENTION: erythromycin 0.5% ointment prophylaxis (covers GC, not chlamydia)
+ maternal prenatal screening/treatment
16. References to Verify
Confirm each against the primary source and current guidance before clinical or published use (resistance is evolving).
- 1.Prophylaxis: AAP Red Book and USPSTF Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum (erythromycin 0.5% ointment; grade A). (Verify.)
- 2.Gonococcal treatment: CDC STI treatment guidelines — neonatal gonococcal ophthalmia (ceftriaxone dosing; hyperbilirubinemia caution). (Verify current dose/resistance.)
- 3.Chlamydial treatment: oral erythromycin/azithromycin × 14 days; pyloric-stenosis association. (Verify.)
- 4.HSV: neonatal HSV ocular disease management (see HSV chapter). (Verify.)
- 5.Prevention strategy: evidence that maternal screening/treatment (vs neonatal prophylaxis alone) prevents chlamydial disease. (Verify.)